Renaissance Technologies LLC Acquires 297,500 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Renaissance Technologies LLC raised its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 53.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 854,900 shares of the company’s stock after purchasing an additional 297,500 shares during the quarter. Renaissance Technologies LLC owned approximately 0.88% of Poseida Therapeutics worth $2,496,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Cantor Fitzgerald L. P. bought a new stake in Poseida Therapeutics during the 4th quarter worth about $169,000. Russell Investments Group Ltd. bought a new position in shares of Poseida Therapeutics in the first quarter worth about $110,000. Blair William & Co. IL lifted its position in shares of Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock worth $3,079,000 after purchasing an additional 282,310 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Poseida Therapeutics by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after purchasing an additional 473,746 shares in the last quarter. Finally, Lazard Asset Management LLC raised its position in Poseida Therapeutics by 280.3% in the 1st quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after purchasing an additional 21,138 shares during the last quarter. Institutional investors own 46.87% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Poseida Therapeutics in a research report on Tuesday, August 6th.

Poseida Therapeutics Stock Down 3.8 %

Shares of NASDAQ PSTX opened at $2.75 on Wednesday. Poseida Therapeutics, Inc. has a 1 year low of $1.83 and a 1 year high of $4.27. The firm’s 50-day moving average is $3.06 and its 200-day moving average is $2.92. The company has a current ratio of 2.48, a quick ratio of 2.48 and a debt-to-equity ratio of 0.97. The firm has a market capitalization of $266.63 million, a PE ratio of -2.31 and a beta of 0.51.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Monday, August 5th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. The firm had revenue of $25.97 million during the quarter, compared to analyst estimates of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. Equities analysts expect that Poseida Therapeutics, Inc. will post -1.57 EPS for the current year.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.